business
Biogen fall 6% despite positive Alzheimer’s drug trial data
Biogen fall 6% despite positive Alzheimer’s drug trial data
Read full story on Investing.com → More top storiesAlso covered by
CNBC
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
STAT News
STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
Yahoo Finance
Regenxbio Shares Rise After Positive Duchenne Trial Results
ARY News
Anmol Pinky: Drug test delay despite examination sparks questions
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop